Delving into the Latest Updates on Southwest Hospital with Synapse

概览

关联

9

项与 Southwest Hospital 相关的临床试验

ChiCTR2400094780

/ SuspendedN/AIIT

The Investigation of Transcription Factor SOX11 and PITX1 in Predicting Meningioma Clinical Outcomes

开始日期2025-01-01

申办/合作机构

Southwest Hospital

ChiCTR1900022467

/ Recruiting早期临床1期IIT

Microarray profiling analysis of non-coding RNAs expression intendinopathy: identification for potential biomarkers and mechanisms

开始日期2019-04-15

申办/合作机构

Southwest Hospital

ChiCTR1900020500

/ RecruitingN/AIIT

Retinal pigment epithelium in healthy subjects observed by multispectral imaging combined with visual electrophysiology

开始日期2019-01-07

申办/合作机构

Southwest Hospital

100 项与 Southwest Hospital 相关的临床结果

登录后查看更多信息

0 项与 Southwest Hospital 相关的专利（医药）

登录后查看更多信息

737

项与 Southwest Hospital 相关的文献（医药）

2025-10-01·Immunology Letters

The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment

Article

作者: Jiang, Jiayun ; Huang, Yulan ; Ou, Yanjiao ; Zhang, Leida ; Lai, Jiejuan ; Fu, Yu ; Zhang, Hui ; Li, Chong ; Cai, Wenyun

BACKGROUNDDespite encouraging clinical benefits have gained by anti-PD-1 and Lenvatinib combination, in-depth characterizations about the mechanisms of action remain poorly characterized. Furthermore, although the combination of systemic anti-PD-1 or Lenvatinib treatment and locoregional transcatheter arterial chemoembolization (TACE) is widely carried out to treat unresectable HCC in clinical, the efficacies of different combination regimens are uncertain due to limited researches.METHODSWe firstly generated murine HCC models to validate the enhanced anti-tumor effects of anti-PD-1 and Lenvatinib combination therapy. Then single cell mass cytometry (CyTOF) was employed to phenotypically reveal their mechanisms of action. After that, we further compared the effectiveness of TACE plus Lenvatinib (i.e., TACE-Len) dual therapy with TACE, Lenvatinib plus anti-PD-1 (i.e., TACE-Len-PD-1) triple therapy as conversion therapy for unresectable HCC.RESULTSLenvatinib and anti-PD-1 combination could generate activated immune profiles not only by increasing systemic CD4⁺, CD8⁺T cells and B cells proportions, but also by weakening the immune-tolerance functions derived from both immunosuppressive cells (i.e., MDSCs) and co-inhibitory mediators (i.e., PD-L1 and LAG-3). Meanwhile, our study also suggested that TACE-Len-PD-1 triple therapy could achieve better clinical responses with powerful immune profiles for unresectable HCC compared to TACE-Len dual therapy.CONCLUSIONSOur study provided a delicate immune landscape of anti-PD-1and Lenvatinib combination, and we also offered scientific evidences that TACE-Len-PD-1 triple therapy could fulfill better clinical benefits than TACE-Len dual therapy, which is anticipated to provide objective and effective evidences for clinical use.

2025-07-01·International Journal of Cardiology

Plasma expression level of Hsa_circ_0099734 is associated with atrial fibrillation and its poor prognosis

Article

作者: Yuan, Zhiquan ; Chen, Xinghua ; Wu, Na ; Xiang, Ying ; Yang, Lanqing ; Zeng, Yuhong ; Zhong, Li ; Wu, Long ; Li, Chengying ; Li, Jun ; Li, Yafei ; Xia, Tingting ; Chen, Yanxiu

BACKGROUNDAtrial fibrillation (AF) is a common arrhythmia characterized by severe complications such as stroke, resulting in high disability and mortality rates. A circular RNA (circRNA) hsa_circ_0099734 was found significantly expressed in the atrial tissue of AF patients and controls in our previous work. In this study, we aim to reveal the association between hsa_circ_0099734 and AF as well as its poor prognosis, offering novel perspectives for clinical treatment.METHODSA 1:1 matched case-control study was designed to examine the association between hsa_circ_0099734 and AF. A prospective cohort study was conducted to investigate the association between hsa_circ_0099734 and AF prognosis using Cox proportional hazards regression analysis.RESULTSAn elevated plasma level of hsa_circ_0099734 was an independent risk factor for AF in a multivariable conditional logistic regression model (OR 3.23, 95 % CI: 1.11-9.44; P = 0.032). Regarding the prognostic role of hsa_circ_0099734, the multivariable Cox regression analysis indicated that a high level of hsa_circ_0099734 in plasma was an independent risk factor for stroke in patients with AF (HR 2.87, 95 % CI: 1.90-4.35; P < 0.001), and also an independent risk factor for all-cause mortality in AF patients (HR 3.16, 95 % CI: 2.25-4.45; P < 0.001). Adding hsa_circ_0099734 to the CHA₂DS₂-VA score provided better reclassification and net clinical benefit than the ABC risk score.CONCLUSIONSThe plasma level of hsa_circ_0099734 was associated with AF risk and the occurrence of stroke or all-cause mortality in AF patients. Hsa_circ_0099734 has the potential to be a non-invasive biomarker for predicting AF and its poor prognosis.

2025-07-01·Genes & Diseases

A causal association between immune cells and hypertrophic cardiomyopathy: A bidirectional Mendelian randomization study

Article